Taylor Hooton Foundation > Hoot’s Corner > General > $30 Billion Supplement Industry needs regulating
April 3, 2014
$30 Billion Supplement Industry needs regulating

Hazards of Hindsight — Monitoring the Safety of Nutritional Supplements

Pieter Cohen, M.D.
Epidemiologists at the Centers for Disease Control and Prevention (CDC) recently confirmed what an astute liver-transplant surgeon in Honolulu already suspected: OxyElite Pro, a popular over-the-counter supplement, was responsible for a cluster of cases of severe hepatitis and liver failure.1Although patients began to develop severe hepatitis in May 2013, the Food and Drug Administration (FDA), whose job it is to remove dangerous supplements from store shelves, did not learn of the cases until mid-September, 4 months later. By February 2014, the CDC had linked 97 cases, resulting in 47 hospitalizations, three liver transplantations, and one death, to OxyElite Pro. This dietary supplement was recalled, but nothing has been done to prevent another supplement from causing organ failure or death. Nor have any changes been made to improve the FDA’s ability to detect dangerous supplements. The FDA’s delayed response — with its life-threatening consequences — is attributable to our woefully inadequate system for monitoring supplement safety. Americans spend more than $32 billion a year on more than 85,000 different combinations of vitamins, minerals, botanicals, amino acids, probiotics, and other supplement ingredients. Unlike prescription medications, supplements do not require premarketing approval before they reach store shelves. Under the Dietary Supplement Health and Education Act of 1994, anything labeled as a dietary supplement is assumed to be safe until proven otherwise. The FDA is charged with the unenviable task of identifying and removing dangerous supplements only after they have caused harm. And the agency has its work cut out for it: potentially dangerous supplements are widely available. More than 500 supplements have already been found to be adulterated with pharmaceuticals or pharmaceutical analogues, including new stimulants, novel anabolic steroids, unapproved antidepressants, banned weight-loss medications, and untested sildenafil analogues.2 In 2013 alone, researchers discovered two new stimulants in widely marketed supplements. My colleagues and I identified a new analogue of methamphetamine, N,α-diethyl-phenylethylamine (N,α-DEPEA), in a popular sports supplement.3 FDA scientists discovered another stimulant, β-methylphenethylamine (β-MePEA) — a novel analogue of amphetamine — in nine supplements.4N,α-DEPEA and β-MePEA have never been studied in humans, and their adverse effects are entirely unknown; yet they are sold as “natural” products without having undergone any premarketing testing for safety. (Although supplements containing N,α-DEPEA were voluntarily withdrawn from the market, supplements containing β-MePEA remain widely available.) Rapid detection of harm from these and other supplements is essential to minimizing risks to consumers. The FDA currently relies on MedWatch (https://www.safetyreporting.hhs.gov), the FDA’s online portal for clinicians to voluntarily report adverse events associated with prescription drugs, medical devices, or dietary supplements. MedWatch suffers from significant underreporting and incomplete reports, which hamper its ability to detect harms even from prescription medications. It is even less effective in detecting adverse effects of supplements, a more complicated task because supplements are sold directly to consumers, often contain multiple active ingredients, and are too often inaccurately labeled. MedWatch reports have rarely provided sufficient and adequately timely data to permit detection of clusters of serious adverse effects from supplements. Instead, local public health departments, the CDC, or the Department of Defense have often been the first to detect harm from supplements. The recent cluster of patients with liver failure in Hawaii is a case in point: MedWatch reports were submitted only after the local department of public health was already investigating supplement use among affected patients. Similarly, in 2008, when a poorly manufactured multivitamin was responsible for more than 200 cases of selenium poisoning — with symptoms including diarrhea, fatigue, hair loss, and joint pain — local health departments cracked the case linking the illness to the multivitamin; MedWatch reports were irrelevant. More recently, in 2011, the Department of Defense removed supplements containing the stimulant 1,3-dimethylamylamine (DMAA) from military bases because of safety concerns. It took the FDA an additional 16 months after the military ban to gather sufficient safety data from MedWatch to alert consumers about DMAA’s risks. Despite a concerted effort by the FDA to remove the stimulant, DMAA remains in dozens of supplements. During the 2014 Winter Olympics, three Olympians were banned for using DMAA — all three reported inadvertently consuming it in supplements. MedWatch also lacks the capacity to provide clinical advice to providers caring for affected patients. Clinicians are often unfamiliar with supplement ingredients and may turn to poison centers, which offer free medical advice after any type of poison exposure. An investigation by the Government Accountability Office revealed that between 2008 and 2010, more than 1000 supplement-related adverse events were reported to poison centers but not reported to the FDA. Because data are not routinely shared between the centers and the agency, the FDA did not have access to any of these reports. What can be done? A bill currently being reviewed by committee, the Dietary Supplement Labeling Act, sponsored by Senators Dick Durbin (D-IL) and Richard Blumenthal (D-CT), would require supplement manufacturers to register their products with the FDA and to provide more safety information, such as information about known adverse effects, to consumers (see tableExamples of Potential Adverse Reactions to Legal Ingredients and Adulterants in Dietary Supplements.). The bill is a step toward ensuring that vitamins, minerals, botanicals, probiotics, and other supplement ingredients are accurately labeled, but it would not improve the FDA’s ability to detect and remove dangerous supplements from store shelves. Sweeping changes would be needed to create an effective surveillance system capable of rapidly detecting supplement-related adverse events in the United States. I believe that accurate information on every supplement sold in this country should be incorporated into databases maintained by both the FDA and poison centers. Appropriate public health responses would be expedited if all key organizations, including the poison centers, the Defense Department, local departments of public health, and manufacturers, shared reports of serious supplement-related adverse events with the FDA in real time. A supplement response team could be created, made up of expert clinicians, toxicologists, pharmacologists, and chemists. The team could be based at the CDC, the FDA, the poison centers, or an academic institution. When consumers or physicians report a serious adverse event, the supplement response team could be alerted immediately. The multidisciplinary team could then offer clinical advice to physicians as they cared for patients, provide detailed reports to the FDA, and analyze patients’ unused supplements for labeled and unlabeled ingredients. Supplement manufacturers could be required to provide complete manufacturing details and additional samples as requested. These changes would ensure not only that the FDA received accurate and timely reports, but also that clinicians received expert clinical advice as they cared for affected patients. A pilot project incorporating several of these principles has already shown that active surveillance of poison-center reports can result in rapid identification of potentially harmful products.5 This successful pilot was terminated, however, because of a lack of funding. With more than half of U.S. adults taking supplements every year, at a cost of billions of dollars, consumers deserve a well-funded surveillance program capable of rapidly detecting hazardous supplements. But even these ambitious changes would not prevent dangerous supplements from reaching consumers. If consumers and physicians are to have confidence that all supplements are safe, the law regulating supplements must be reformed. Every supplement ingredient should undergo rigorous safety testing before marketing. Until that happens, consumers and physicians cannot be assured that the pills, powders, and potions labeled as dietary supplements are safe for human consumption. http://www.nejm.org/doi/full/10.1056/NEJMp1315559#.Uz2cgyw5M0Y.twitter